Skip to main content
 
  • Deutsch
  • English
Kontakt

Vielen Dank für Ihre Nachricht.

Wir werden uns umgehend mit Ihnen in Verbindung setzen.

13.06.18

NEW RELEASE & AUTHOR FEEDBACK: "Quo vadis cancer therapy ?: Fascinating discoveries of the last 60 years"

Prof. Dr. Volker Schirrmacher

A review by Prof. Dr. rer. Nat. Achim Krüger, Klinikum rechts der Isar der Technischen Universität München, Institut für Molekulare Immunologie und Experimentelle Onkologie, München, Germany

 It is one of the common truths that we need to know where we came from in order to appreciate the present and to responsibly proceed to the future. In fact, ‘Quo vadis cancer therapy. Fascinating discoveries of the last 60 years’ encompasses this truth providing an in-depth account of past and present modern cancer research, as well as a timely perspective for what could be achieved soon in the race to find efficient therapies for cancer. The author, Volker Schirrmacher, who spent most of his successful career as a Professor for Tumor Immunology at the German Cancer Research Center in Heidelberg, is eye-witness, authority, and one of the most consequent proponents of the development of new therapies of cancer exhibiting more efficacy and less side effects.      

Schirrmacher takes the reader through the problems and limitations of conventional cancer therapies and provides comprehensive insight into the actual nature of cancer disease, which is complex, affects the entire organism, and spreads throughout the body in the deadly process of metastasis. The guiding theme of the book is that this complex nature of cancer has to be met with sophisticated therapy approaches and is not sufficiently responsive to simple therapy solutions. The book enables the Reader to appreciate cancer as a disease that can be overcome only when resources of the body are involved in the elimination of the deadly metastases. Schirrmacher points at the importance of the immune system in the fight against cancer, and clearly and extensively describes how modern cancer research slowly but surely opened the way for immunotherapy against cancer, too slow for the author’s taste as quite a few spicy remarks in the book indicate. Schirrmacher shares many personal experiences and his own contributions to the field giving the book a fascinating introduction into a scientist’s life and struggle. The conveyed message to students and young researchers is that it is worthwhile and necessary that scientists maintain sustained interest, self-confidance, and endurance.      

‘Quo vadis cancer therapy’ is an important read for scientists and medical doctors in this research field and a benefit for students of life sciences or medicine, as well as for patients and other people who have an interest in the victory over the dreadful disease of cancer.  

 

Imprint: LAP Lambert Academic Publishing

Prof. Dr. Volker Schirrmacher, author of the book:

 Quo vadis cancer therapy ?: Fascinating discoveries of the last 60 years

 

Fascinating discoveries have been made in the last 60 years in cancer research. Yet, these discoveries have not changed the main methods of standard cancer treatment. Surgery, radiotherapy and chemotherapy were developed in the first half of the 20th century. At this time nothing was known about the biology of cancer metastasis and about the role of the immune system in the fight against cancer. This book is a plea for an update of cancer treatment by including biology-based treatments, such as immunotherapy and oncolytic virotherapy. These treatments have a higher tumor selectivety and lower side effects than radio-or chemotherapy. In addition they can induce long-lasting effects which are based on cancer-specific immunological memory. We now know that epigenetic mechanisms allow tumors to develop therapy-resistant variants. Therefore, efficacy of future cancer therapy could be improved by targeting cancer-associated epigenetic mechanisms. The tumor microenvironment represents an important support system for cancer growth, invasion and metastasis. Future strategies targeting the tumor microenvironment are considered as promising. The book addresses all people concerned with cancer.